Art. -Nr.: HY-13311

Infigratinib

Name: Infigratinib
Brand: MedChemExpress
SKU: HY-13311
Price: 50.00 USD
Availability: InStock
Rating: 5 (49 reviews)

(Synonyms: BGJ-398; NVP-BGJ398)

49 Cited Publications

Kundenbewertung

Based on 49 publication(s) in Google Scholar

Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.82%
CAS. Nr.: 872511-34-7
Formel: C₂₆H₃₁Cl₂N₇O₃
Molecular Weight:560.48

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Infigratinib Chemical Structure

CAS. Nr.: 872511-34-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (49)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

IC₅₀ & Target

^[1]

FGFR1

0.9 nM (IC₅₀)

FGFR2

1.4 nM (IC₅₀)

FGFR3

1 nM (IC₅₀)

FGFR4

60 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
AN3-CA	GI₅₀	0.039 μM Compound: 1	Antiproliferative activity against human AN3-CA cells harboring FGFR2 K310R/N549K mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against human AN3-CA cells harboring FGFR2 K310R/N549K mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	>5 μM Compound: 1	Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	>5 μM Compound: 1	Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR4 N535K mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR4 N535K mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	0.005 μM Compound: 1	Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR3 assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR3 assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	2.605 μM Compound: 1	Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR3-V555M mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR3-V555M mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	4.005 μM Compound: 1	Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR4 V550E mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR4 V550E mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	IC₅₀	132.6 nM Compound: 2;BGJ-398	Antiproliferative activity against mouse BAF3 cells expressing TEL-fused FGFR4 kinase after 72 hrs by CCK8 or MTT assay Antiproliferative activity against mouse BAF3 cells expressing TEL-fused FGFR4 kinase after 72 hrs by CCK8 or MTT assay	[PMID: 29522671]
BaF3	IC₅₀	3343.8 nM Compound: 2;BGJ-398	Antiproliferative activity against mouse BAF3 cells expressing TEL-fused KDR kinase after 72 hrs by CCK8 or MTT assay Antiproliferative activity against mouse BAF3 cells expressing TEL-fused KDR kinase after 72 hrs by CCK8 or MTT assay	[PMID: 29522671]
Hep 3B2	IC₅₀	85 nM Compound: Infigratinib	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability by cell proliferation assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability by cell proliferation assay	[PMID: 32930584]
Huh-7	IC₅₀	57.2 nM Compound: 2;BGJ-398	Antiproliferative activity against FGF19/FGFR4 expressing human HuH7 cells after 72 hrs by CCK8 or MTT assay Antiproliferative activity against FGF19/FGFR4 expressing human HuH7 cells after 72 hrs by CCK8 or MTT assay	[PMID: 29522671]
Huh-7	IC₅₀	80 nM Compound: Infigratinib	Antiproliferative activity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by cell proliferation assay Antiproliferative activity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by cell proliferation assay	[PMID: 32930584]
J82	GI₅₀	3.345 μM Compound: 1	Antiproliferative activity against human J82 cells harboring FGFR3 K652E mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against human J82 cells harboring FGFR3 K652E mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
KATO III stomach cancer cell line	IC₅₀	60.3 nM Compound: BGJ398	Antiproliferative activity against human KATO III stomach cancer cell line assessed as reduction in cell viability measured for 72 hrs by celltiter-glo reagent based assay Antiproliferative activity against human KATO III stomach cancer cell line assessed as reduction in cell viability measured for 72 hrs by celltiter-glo reagent based assay	[PMID: 37220310]
KMS-11	GI₅₀	0.22 μM Compound: 1	Antiproliferative activity against human KMS-11 cells harboring FGFR3 Y373C mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against human KMS-11 cells harboring FGFR3 Y373C mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
NCI-H716	IC₅₀	65.9 nM Compound: BGJ398	Antiproliferative activity against human NCI-H716 cells assessed as reduction in cell viability measured for 72 hrs by celltiter-glo reagent based assay Antiproliferative activity against human NCI-H716 cells assessed as reduction in cell viability measured for 72 hrs by celltiter-glo reagent based assay	[PMID: 37220310]
RT-112	IC₅₀	<0.5 nM Compound: 2;BGJ-398	Antiproliferative activity against FGFR3 amplified human RT112 cells after 72 hrs by CCK8 or MTT assay Antiproliferative activity against FGFR3 amplified human RT112 cells after 72 hrs by CCK8 or MTT assay	[PMID: 29522671]
RT-112	IC₅₀	10 nM Compound: Infigratinib	Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
RT-112	IC₅₀	218 nM Compound: Infigratinib	Antiproliferative activity against human RT-112 cells expressing FGFR3 K650M mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells expressing FGFR3 K650M mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
RT-112	IC₅₀	352 nM Compound: Infigratinib	Antiproliferative activity against human RT-112 cells expressing FGFR3 V555M mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells expressing FGFR3 V555M mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
RT-112	IC₅₀	6.2 nM Compound: Infigratinib	Antiproliferative activity against human RT-112 cells assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
RT-112	IC₅₀	777 nM Compound: Infigratinib	Antiproliferative activity against human RT-112 cells expressing FGFR3 N540K mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells expressing FGFR3 N540K mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
Sf9	IC₅₀	2.7 nM Compound: 3	Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition a Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition a	[PMID: 36356320]
SNU-16	IC₅₀	12.4 nM Compound: Infigratinib	Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
SNU-16	IC₅₀	95.4 nM Compound: BGJ398	Antiproliferative activity against human SNU-16 cells assessed as reduction in cell viability measured for 72 hrs by celltiter-glo reagent based assay Antiproliferative activity against human SNU-16 cells assessed as reduction in cell viability measured for 72 hrs by celltiter-glo reagent based assay	[PMID: 37220310]

In Vitro

Infigratinib (BGJ-398) inhibits FGFR1, FGFR2, and FGFR3 with IC₅₀=~1 nM, FGFR3^K650E with IC₅₀=4.9 nM, and FGFR4 with IC₅₀=60 nM. IC₅₀ values for all other kinases are in the μM range (FYN, LCK, YES, and ABL, IC₅₀=1.9, 2.5, 1.1, and 2.3 μM, respectively) except for VEGFR2, KIT, and LYN, which are inhibited at submicromolar concentrations (IC₅₀=0.18, 0.75, and 0.3 μM, respectively).
Infigratinib (BGJ-398) inhibits the proliferation of the FGFR1-, FGFR2-, and FGFR3-dependent BaF3 cells with IC₅₀ values which are in the low nanomolar range and comparable to those observed for the inhibition of the receptors kinase activity in the enzymatic assay.
For the remaining cells, all IC₅₀ values are greater than 1.5 μM except for VEGFR2 (IC₅₀ 1449 and 938 nM), for which there is at least a 400-fold selectivity versus FGFR1, FGFR2, and FGFR3^[1].
Infigratinib (BGJ-398) (ranging between 1 nM and 10 μM) is potent at inhibiting cell growth of FGFR2-mutant endometrial cancer cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .

In Vivo

Infigratinib (BGJ-398) is administered to athymic nude mice implanted subcutaneously with RT112/luc1 tumors: either as a 5 mg/kg intravenous bolus in NMP/PEG200 (1:9, v/v) or orally by gavage as a suspension in PEG300/D5W (2:1, v/v) at a 20 mg/kg dose.The relevant pharmacokinetic (PK) parameters indicate that the oral bioavailability of Infigratinib (BGJ-398) in this study is 32%. After intravenous dosing, Infigratinib (BGJ-398) shows a rapid distribution from the vascular compartment into the peripheral tissues, translating into a high volume of distribution (26 L/kg). The plasma clearance is high at 3.3 L/h/kg (61% of liver blood flow). The ratio of tumor to plasma after oral dosing based on AUC is determined to be 10^[1].
Infigratinib (BGJ-398) (30 mg/kg) significantly inhibits the growth of FGFR2-mutated endometrial cancer xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 872511-34-7
Appearance Solid
Molecular Weight 560.48
Formel C₂₆H₃₁Cl₂N₇O₃
Color White to yellow
SMILES

ClC1=C(C(Cl)=C(C=C1OC)OC)NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)CC)=NC=N2)C)=O
Synonyms

BGJ-398; NVP-BGJ398
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (49)

All WBFlow CytometryRT-PCRIFIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research. [Abstract]

2025 Nov 4;10(1):361. PMID: 41184234
Signal Transduct Target Ther

Microglia-derived nanovesicles synchronize macroautophagy and chaperone-mediated autophagy for Alzheimer's disease therapy. [Abstract]

2025 Nov 3;10(1):360. PMID: 41184271
Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. [Abstract]

2022 Aug;608(7923):609-617. PMID: 35948633
Cancer Discov

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. [Abstract]

2019 Dec;9(12):1686-1695. PMID: 31575540
Cancer Discov

Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. [Abstract]

2018 Mar;8(3):354-369. PMID: 29203461

Infigratinib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2018 Mar;8(3):354-369. [Abstract]

BGJ398 (30-50 mg/kg; oral). In vivo dosing of BGJ398 at 30mg/kg achieves target inhibition measured by pFrs2 and pErk levels.

Infigratinib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2018 Mar;8(3):354-369. [Abstract]

BGJ398 (30-50 mg/kg; oral). Combining BGJ398 and a different PARP-inhibitor, BMN673, induces sustained tumor remission.
Ann Rheum Dis

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. [Abstract]

2016 May;75(5):883-90. PMID: 25858641
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Accurate determination of CRISPR-mediated gene fitness in transplantable tumours. [Abstract]

2022 Aug 4;13(1):4534. PMID: 35927228
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
J Exp Clin Cancer Res

Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma. [Abstract]

2021 Aug 27;40(1):273. PMID: 34452627

Infigratinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Aug 27;40(1):273. [Abstract]

BGJ398 (10 nM; 24 h). Western blotting was performed to examine the effect of cyclin G2 on Y10 phosphorylation of LDHA in the presence or absence of BGJ398.
J Control Release

New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. [Abstract]

2018 Sep 28:286:254-263. PMID: 30075209
Cell Death Dis

FGFR inhibitors promote the autophagic degradation of IFN-γ-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer. [Abstract]

2025 Jul 2;16(1):485. PMID: 40603902

Infigratinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jul 2;16(1):485. [Abstract]

BGJ398 (0-80 nM; 48 h). RT4 cells were treated with vehicle control or the indicated concentrations of BGJ398 in the presence or absence of interferon (IFN)-γ (10 ng/ml) for 48 h and subjected to western blot analysis.

Infigratinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jul 2;16(1):485. [Abstract]

RT-112 cells were exposed to IFN-γ (10 ng/ml) with or without L145 (2 μM) or BGJ398 (0.08 μM) for 48 h, stained with αPD-L1 antibody, and subjected to flow cytometry analysis.

Infigratinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jul 2;16(1):485. [Abstract]

BGJ398 (0.04 μM; 6-48 h). RT-112 cells were treated with vehicle control (CTRL) or IFN-γ (10 ng/ml) with or without L145 (1 μM) or BGJ398 (0.04 μM) for the indicated times, and subjected to RT-qPCR analyses.

Infigratinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jul 2;16(1):485. [Abstract]

RT-112 cells were treated with interferon (IFN)-γ (10 ng/ml) alone or in combination with L145 (1 μM) or BGJ398 (0.08 μM) for 24 h and subjected to immunofluorescence staining with antibodies against PD-L1 (green) and LC3B (red).
J Neuroinflammation

The FGF/FGFR system in the microglial neuroinflammation with Borrelia burgdorferi: likely intersectionality with other neurological conditions. [Abstract]

2023 Jan 17;20(1):10. PMID: 36650549
NPJ Precis Oncol

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. [Abstract]

2021 Jul 16;5(1):66. PMID: 34272467
Oncogene

YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. [Abstract]

2016 Apr 28;35(17):2247-65. PMID: 26364602
Cell Rep

IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth. [Abstract]

2024 Dec 30;44(1):115116. PMID: 39739531
Cell Rep

Germline Stem Cells Drive Ovary Regeneration in Zebrafish. [Abstract]

2019 Feb 12;26(7):1709-1717.e3. PMID: 30759383
J Med Chem

Discovery of Novel 2,4,5-Trisubstituted Pyrimidine Derivatives as Potent and Selective FGFR Inhibitors against Gatekeeper Mutants for the Treatment of NSCLC. [Abstract]

2025 Mar 13;68(5):5907-5925. PMID: 40032550
Pharmaceutics

8-Hydroxy-2-Anilino-1,4-Naphthoquinone Prevents Against Ferroptotic Neuronal Death and Kainate-Induced Epileptic Seizures. [Abstract]

2025 Oct 31;17(11):1415. PMID: 41304754
Cell Mol Life Sci

ALKBH5 demethylation modification of SE-lncRNA ZMIZ1-AS1 promotes FGFR1-mediated proliferation and invasive metastasis in osteosarcoma. [Abstract]

2025 Nov 22. PMID: 41275058
RSC Adv

Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites. [Abstract]

2020 Apr 23;10(28):16231-16244. PMID: 35498820
Biochim Biophys Acta Mol Basis Dis

Combined inhibition of EGFR and FGFRs with Cetuximab and Infigratinib showed effectiveness and relevance in proliferation and migration of HNSCC cell lines. [Abstract]

2025 Oct;1871(7):167940. PMID: 40449758
Obesity (Silver Spring)

Fibroblast Growth Factor 21 Exerts its Anti-inflammatory Effects on Multiple Cell Types of Adipose Tissue in Obesity. [Abstract]

2019 Mar;27(3):399-408. PMID: 30703283
Sci Rep

Up-regulation of FGFBP1 signaling contributes to miR-146a-induced angiogenesis in human umbilical vein endothelial cells. [Abstract]

2016 Apr 28:6:25272. PMID: 27121396
Cancers (Basel)

TMEM176B Promotes EMT via FGFR/JNK Signalling in Development and Tumourigenesis of Lung Adenocarcinoma. [Abstract]

2024 Jul 3;16(13):2447. PMID: 39001509
Biomedicines

Tephrosin Suppresses the Chemoresistance of Paclitaxel-Resistant Ovarian Cancer via Inhibition of FGFR1 Signaling Pathway. [Abstract]

2023 Nov 27;11(12):3155. PMID: 38137377
Biochim Biophys Acta Mol Cell Res

2026 Jul 21;1873(7):120196. PMID: 42480940
Chem Res Toxicol

Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib. [Abstract]

2021 Jul 19;34(7):1800-1813. PMID: 34189909
Development

Specific mitotic events drive left-right organizer development. [Abstract]

2025 May 15;152(10):dev204687. PMID: 40230260
Biotechnol J

Discovery of fibroblast growth factor 2-derived peptides for enhancing mice skeletal muscle satellite cell proliferation. [Abstract]

2024 Aug;19(8):e2400278. PMID: 39212202
Peptides

FGF9 drives mitochondrial biogenesis in glioblastoma by activating the CREB-PGC-1α axis. [Abstract]

2026 Jan:195:171463. PMID: 41485715
Tissue Eng Part A

Integration Capacity of Human Induced Pluripotent Stem Cell-Derived Cartilage. [Abstract]

2019 Mar;25(5-6):437-445. PMID: 30129877
FEBS Open Bio

Reduced FRG1 expression promotes angiogenesis via activation of the FGF2-mediated ERK/AKT pathway. [Abstract]

2023 May;13(5):804-817. PMID: 36815234
Thorac Cancer

Establishing a new human lung squamous cell carcinoma cell line, OMUL-1, expressing insulin-like growth factor 1 receptor and programmed cell death ligand 1. [Abstract]

2025 Jan;16(1):e15488. PMID: 39552203
Anticancer Drugs

Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models. [Abstract]

2023 Oct 1;34(9):1035-1045. PMID: 36729099
SSRN

2026 May 20.
bioRxiv

Disruption of the FGFR1-FGF23-Phosphate Axis and Targeted Therapy in a Murine Model of Osteoglophonic Dysplasia. [Abstract]

2025 Nov 14:2025.11.14.680268. PMID: 41473314
Biomed Pharmacother

FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma. [Abstract]

2025 Nov:192:118677. PMID: 41124865
University of Auckland

2025.
Res Sq

2025 Jul 24.
World J Exp Med

Establishment and characterization of a new human gallbladder cancer cell line, OCUG-2. [Abstract]

2025 Jun 20;15(2):100443. PMID: 40546672
bioRxiv

A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. [Abstract]

2025 Jun 16:2025.06.11.659120. PMID: 40667115
bioRxiv

Specific Mitotic Events Drive Cytoskeletal Remodeling Required for Left-Right Organizer Development. [Abstract]

2024 Oct 1:2024.05.12.593765. PMID: 38798489
Heliyon

Dual blockage of PI3K-mTOR and FGFR induced autophagic cell death in cholangiocarcinoma cells. [Abstract]

2024 May 10;10(10):e31112. PMID: 38799762
medRxiv

2023 Mar 17.
Patent

US20220175722A1.
The 22nd National Graduate Research Conference

2021 Mar 25.
Oncotarget

MEK is a promising target in the basal subtype of bladder cancer. [Abstract]

2020 Nov 3;11(44):3921-3932. PMID: 33216841
Tag der mündlichen Prüfung

2016.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 12 mg/mL (21.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7842 mL

8.9209 mL

17.8419 mL

5 mM

0.3568 mL

1.7842 mL

3.5684 mL

10 mM

0.1784 mL

0.8921 mL

1.7842 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.67 mg/mL (2.98 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (2.98 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.57 mg/mL (2.80 mM); Clear solution

This protocol yields a clear solution of ≥ 1.57 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 0.6 mg/mL (1.07 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.6 mg/mL (1.07 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Guagnano V, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T [Content Brief]

[2]. Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42. [Content Brief]

[3]. Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7842 mL	8.9209 mL	17.8419 mL	44.6046 mL
	5 mM	0.3568 mL	1.7842 mL	3.5684 mL	8.9209 mL
	10 mM	0.1784 mL	0.8921 mL	1.7842 mL	4.4605 mL
	15 mM	0.1189 mL	0.5947 mL	1.1895 mL	2.9736 mL
	20 mM	0.0892 mL	0.4460 mL	0.8921 mL	2.2302 mL

Bioz

Keywords

Infigratinib

49 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Infigratinib

Publications Citing Use of MedChemExpress (MCE) Infigratinib